Carisma Therapeutics Inc. and OrthoCellix, a subsidiary of Ocugen, have announced a definitive merger agreement to create a Nasdaq-listed regenerative cell therapy company. The merger, which will be ...
Company to explore strategic alternatives to advance liver fibrosis and oncology assets and reduce operational cash burn PHILADELPHIA, March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (CARM) ( ...
The posters presented at SITC 2024 will be available online in the "Publications" section of Carisma's website at https://carismatx.com/technology/publications ...
PHILADELPHIA, March 31, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company") today announced that its Board of Directors has approved a revised operating plan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback